Aimei Health Technology Co., Ltd
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 25 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 20 May 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 21 Apr 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 01 Apr 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 14 Nov 2025, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →Aimei Health Technology Co., Ltd — Overview & Financial Snapshot
Aimei Health Technology Co., Ltd (NasdaqGM: AFJK) is a Financial Services company, ranked #1,345 of 6,774 companies globally and #287 of 4,000 in United States on PositoAI, with a Positivity Score of 22,917. Its market capitalisation is ₹361.64 Cr ($38.31M), P/E ratio is 172.9 and P/B ratio is 4.79. It currently has 3 active red flags (PosiRed) and 2 yellow flags (PosiYellow, 6/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →